Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.58 |
| ▸ | LCK | P06239 | 4/20 | 0.58 |
| ▸ | SRC | P12931 | 4/20 | 0.58 |
| ▸ | HCK | P08631 | 3/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | YES1 | P07947 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | FGR | P09769 | 1/20 | 0.58 |
| ▸ | TEC | P42680 | 1/20 | 0.58 |
| ▸ | TXK | P42681 | 1/20 | 0.58 |
| ▸ | BLK | P51451 | 1/20 | 0.58 |
| ▸ | BMX | P51813 | 1/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296676 | 0.86 | BTK (0.66) | BTKLCKSRCHCKFYN | |
| SCHEMBL13860550 | 0.82 | BTK (0.70) | BTKLCKSRCHCKFYN | |
| SCHEMBL13860549 | 0.82 | BTK (0.70) | BTKLCKSRCHCKFYN | |
| SCHEMBL15516942 | 0.76 | SRC (0.79) | BTKLCKSRCHCKFYN | |
| SCHEMBL13858297 | 0.76 | SRC (0.79) | BTKLCKSRCHCKFYN | |
| SCHEMBL6461724 | 0.75 | BTK (0.60) | BTKLCKSRCHCKFYN | |
| SCHEMBL6464776 | 0.75 | BTK (0.60) | BTKLCKSRCHCKFYN | |
| SCHEMBL6462070 | 0.75 | SRC (0.78) | BTKLCKSRCHCKFYN | |
| SCHEMBL30054291 | 0.75 | SRC (0.78) | BTKLCKSRCHCKFYN | |
| SCHEMBL7010960 | 0.74 | LCK (0.72) | BTKLCKSRCHCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | BTK 1/4885LCK 8/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.